While second -
stage results showed no significant differences between participants continuing to receive weekly doses
of the active drug, those receiving biweekly doses and those shifted to placebo, Kimball notes that, since it is typical for the severity
of HS symptoms to increase and decrease and because the study protocol required
treatment discontinuation for participants whose symptoms stopped responding to the drug, larger scale studies will be required to better
define the ideal length and frequency
of treatment.
For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early
stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable
of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status
of 0 - 1 • Available tissue
of primary lung tumor Exclusion Criteria: • Presence
of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior
treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol
defined inclusion / exclusion criteria could apply